Abstract
Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / genetics*
-
Adenocarcinoma / secondary
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Drug Resistance, Neoplasm / genetics
-
Gefitinib
-
Genes, erbB-1 / drug effects*
-
Genes, erbB-1 / genetics
-
Humans
-
Laminectomy
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Magnetic Resonance Imaging
-
Male
-
Middle Aged
-
Mutation*
-
Predictive Value of Tests
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Quinazolines / pharmacology
-
Quinazolines / therapeutic use*
-
Spinal Neoplasms / diagnosis
-
Spinal Neoplasms / genetics
-
Spinal Neoplasms / secondary*
-
Spinal Neoplasms / surgery
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Quinazolines
-
Gefitinib